Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Date publication

mai 2018

Journal

Vox sanguinis

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOHRER Cécile , Pr HERBRECHT Raoul , Dr OJEDA-URIBE Mario

Tous les auteurs :
Herbrecht R, Ojeda-Uribe M, Kientz D, Fohrer C, Bohbot A, Hinschberger O, Liu KL, Remy E, Ernst C, Lin JS, Corash L, Cazenave JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29786866

Résumé

Auto-immune thrombotic thrombocytopenic purpura (TTP) is a morbid multi-organ disorder. Cardiac involvement not recognized in initial disease descriptions is a major cause of morbidity. Therapeutic plasma exchange (TPE) requires exposure to multiple plasma donors with risk of transfusion-transmitted infection (TTI). Pathogen inactivation (PI) with amotosalen-UVA, the INTERCEPT Blood System for Plasma (IBSP) is licensed to reduce TTI risk.

Mots clés

cardiac diseases, infection, plasmapheresis, thrombotic thrombocytopenic purpura, transfusion medicine, transfusion reaction

Référence

Vox Sang.. 2018 May 21;: